Event

Manuel Quaresma

PharmD
Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, and Center for Interstitial and Rare ;Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, and Center for Interstitial

Michael Kreuter

MD, PhD
Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Care Medicine, Thoraxklin;Center for interstitial and rare lung diseases, Pneumology, Thoraxklinik, University of Heidelberg,

Carlo Vancheri

M.D.
Inst of Respiratory Diseases;Universita degli Studi di Catania;University of Catania

Wibke Stansen

PhD
Boehringer Ingelheim Pharma GmbH & Co. KG

Christopher J. Ryerson

M.D.
Centre for Heart Lung Innovation, University of British Columbia;Univeristy of British Columbia and St. Paul's Hospital;University of British Columbia

Wim Wuyts

MD, PhD
KU Leuven;University Hospitals Leuven;University of Leuven

Dominique Valeyre

MD, PhD
Assistance Publique-Hôpitaux de Paris, Avicenne Hospital University;Hopital Avicenne;Hôpital Avicenne, AP-HP

Susanne Stowasser

M.D.
Boehringer Ingelheim Pharma GmbH & Co. KG

Luca Richeldi

MD, PhD
Catholic University of the Sacred Heart;Università Cattolica del Sacro Cuore, Fondazione Policlinico A. Gemelli

Jan C. Grutters

M.D.
Department of Pulmonology ILD Center of Excellence St. Antonius Hospital Nieuwegein & University Med;St. Antonius Hospital, and Division of Heart & Lungs, University Medical Center Utrecht

Gastrointestinal Adverse Events with Nintedanib with Add-On Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF): Further Analyses of INJOURNEY